AVTX Stock Forecast: Avalo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.76
+0.15% on the day

The median 12-month analyst price target for Avalo Therapeutics, Inc. is $34. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$390.3M
Ticker Nerd rank
29/ 100
Median analyst target
$34
Analysts covering
14
Revenue$0.0
Operating income−$31.5M
Net income−$36.4M
Free cash flow−$20.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.9%
1M
−45.3%
YTD
−62.8%
1Y
−61.9%
From 52W high
−70.4%
From 52W low
+2.0%
$7
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Avalo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
70
Revisions
62
Growth
55
Accruals
36
Volatility
30
Issuance
23
Value
19
Momentum
19

Quality (70): The business earns solid, repeatable profits on what it owns.

Momentum (19): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AVTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26AVTXHigh $60Median $34Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12
Buy
2
Hold
0
Sell
$10
Low
$34
Median
$60
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
6 Nov 2026WedbushMaintainsOutperform$22 → $20
23 Oct 2026BTIGMaintainsBuy$58 → $10
23 Oct 2026GuggenheimDowngradeNeutral—
23 Oct 2026HC Wainwright & Co.DowngradeNeutral—
23 Oct 2026WedbushMaintainsOutperform$34 → $22
7 Aug 2026GuggenheimMaintainsBuy$50 → $48
7 Aug 2026HC Wainwright & Co.MaintainsBuy$35 → $30
6 July 2026Leerink PartnersInitiatesOutperform$38
16 June 2026BTIGReiteratesBuy—
12 June 2026B of A SecuritiesInitiatesBuy—
14 May 2026CitizensMaintainsMarket Outperform—
14 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
14 May 2026WedbushMaintainsOutperform—
11 May 2026Piper SandlerMaintainsOverweight—
6 May 2026BTIGMaintainsBuy—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026WedbushMaintainsOutperform—
13 Apr 2026BTIGReiteratesBuy—
9 Apr 2026Wolfe ResearchInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AVTX.

Market Radar

This page is one stock. Monday covers all of them.

AVTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AVTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Avalo Therapeutics, Inc. returned −61.9% against +6.9% for the S&P 500, dividends included.

AVTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26AVTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
6625.2×

Cheaper than 1% of US stocks

Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−33.6%

Higher than 27% of US stocks

Return on assets
−19.7%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Avalo Therapeutics, Inc. has a market value of $390.3M.

  • Revenue in the twelve months to 30 June 2026: $59K.

  • Net income over the same four quarters: −$100.3M, a −170055.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$68.3M.

  • Shares outstanding: 52.9M.

  • Avalo Therapeutics, Inc. employs 33 people — $2K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AVTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVTXAvalo Therapeutics, Inc.$390.3M29
CADLCandel Therapeutics, Inc.$395.4M43
IRDOpus Genetics, Inc.$385.7M39
TVGNTevogen, Inc.$405.2M17
RZLTRezolute, Inc.$375.1M42
OVIDOvid Therapeutics, Inc.$410.6M47
CRMDCorMedix, Inc.$410.8M63

Take a look at AVTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Avalo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AVTX

What is the AVTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Avalo Therapeutics, Inc. is $34, with estimates ranging from $10 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVTX stock a buy right now?

Of the 14 analysts covering Avalo Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalo Therapeutics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVTX?

As at 21 Nov 2026, Avalo Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (70 of 100).

Will AVTX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts is $34, and Ticker Nerd's factor model ranks Avalo Therapeutics, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVTX stock forecast for 2030?

No analyst covering Avalo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $60 over the next 12 months.

How has AVTX stock performed over the past year?

Avalo Therapeutics, Inc. returned -61.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Avalo Therapeutics, Inc. do?

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions.

Company

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions. Avalo Therapeutics also maintains a pipeline that includes additional immune-focused programs, reflecting its emphasis on targeting dysregulated inflammation through biologic therapies. Based in Wayne, Pennsylvania, and incorporated in 2011, the company operates within the immunology and inflammation space, where its products are aimed at diseases with significant unmet medical need.

CEO Dr. Garry A. Neil M.D. · 33 employees · United States · https://www.avalotx.com